Note 11 - Other income, net:


	Nine months ended September 30,
	2011			2012
	(In millions)
Securities earnings:
Dividends and interest	$	22.0		$	21.3
Securities transactions, net		(.6	)		.2

Total		21.4			21.5
Equity in earnings of investee		(.3	)		(.1	)
Currency transactions, net		.8			(.6	)
Insurance recoveries		16.6			2.6
Litigation settlement gain		—			14.7
Reversal of accrued contingent consideration		—			.8
Patent litigation settlement gain		7.5			—
Other, net		.7			1.2

Total	$	46.7		$	40.1

Insurance recoveries reflect, in part, amounts we received from certain of our former insurance carriers and relate to the recovery of prior lead pigment and asbestos litigation defense costs incurred by NL.

In March 2011, CompX entered into a confidential settlement agreement under which CompX’s Canadian subsidiary received approximately $7.5 million in cash which was recognized as a patent litigation settlement gain.

In May 2012, NL reached an agreement with the New Jersey governmental authority and the real estate developer pursuant to which NL received an aggregate of $15.6 million cash for the third and final closing contemplated by the October 2008 settlement agreement associated with certain real property NL formerly owned in New Jersey, as more fully described in Note 17 in our 2011 Annual Report. Upon NL’s receipt of these cash proceeds, our equitable lien on a portion of such property was released. For financial reporting purposes, we have accounted for the consideration received in each of the first, second and third closings contemplated by the October 2008 settlement agreement by the full accrual method of accounting for real estate sales (since the settlement agreement arose out of a dispute concerning the adequacy of the condemnation proceeds of our former real property in New Jersey). Under this method, we recognized a pre-tax gain of approximately $14.7 million in the second quarter of 2012, based on the excess of the $15.6 million cash proceeds received over our carrying value of the property from which our equitable lien was released. Similarly, the cash received in the third closing is reflected as an investing activity in our Condensed Consolidated Statement of Cash Flows.

As discussed in our 2011 Annual Report, there was potential additional cash consideration related to the Components Products Segment’s ergonomics healthcare product line acquired in July 2011, in an amount ranging from nil to approximately $1.5 million, which would have been payable in the first quarter of 2013. The payment was contingent upon the achievement of certain acquired product line sales targets during 2012. The estimated fair value of such accrued consideration had been determined using a probability-weighted discounted cash flow methodology (Level 3 inputs as defined by ASC Topic 820-10-35), using a discount rate of approximately 4%. During the first nine months of 2012, the amount of the increase in accrued contingent consideration for the passage of time was not material. At September 30, 2012, our Component Products Segment determined that it was remote that the sales target necessary for the minimum-level payout would be met and therefore the total amount of the contingent consideration liability was reversed into income. As a result, we recognized approximately $.8 million in other income related to such reversal for the third quarter of 2012.